Search results
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 7 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.